DoMore Diagnostics and leading centers in France Announce Clinical Collaboration on AI-based Histotype Px® Colorectal Biomarker
OSLO – December 12, 2025 – DoMore Diagnostics, a leader in AI precision medicine for cancer, today announced a collaboration with The French-speaking Federation of Digestive Cancer (FFCD, Fédération Francophone de Cancérologie Digestive) and The Centre Hospitalier Universitaire Dijon Bourgogne (CHU Dijon) to clinically validate the Histotype Px® Colorectal (Histotype Px) digital biomarker in colorectal cancer (CRC) using samples from the CIRCULATE-FRANCE PRODIGE 70 clinical trial.
This collaboration aims to evaluate the prognostic performance of Histotype Px Colorectal alone and in combination with circulating tumor DNA (ctDNA) in stage II colorectal cancer patients who have undergone surgical resection.
The clinical validation will include a cohort of 500 patients from the CIRCULATE-FRANCE PRODIGE 70 trial, which investigates minimal residual disease and recurrence risk through ctDNA and other biomarkers. The study will assess whether Histotype Px can be used to independently stratify patient risk in a French cohort and whether combining Histotype Px with ctDNA data provides superior risk assessment compared to either biomarker alone.
“We are delighted to collaborate with DoMore Diagnostics on this important validation of their AI-powered digital biomarker. Personalizing adjuvant therapy decisions in colorectal cancer remains a major clinical need, and current biomarkers cannot adequately identify patients who benefit from adjuvant chemotherapy and not. Integrating digital pathology with ctDNA could represent a major step forward,” said Professor Julien Taieb, Principal Investigator and head of international relations at the FFCD.
“We are honored to work with the great investigators at the FFCD and CHU Dijon, who are internationally recognized for their leadership in driving gastrointestinal oncology forward. This collaboration allows us to independently validate Histotype Px in a large and well-characterized French patient cohort and explore further how combining our digital biomarker with ctDNA can enable more precise treatment decisions,” said Torbjørn Furuseth, MD, CEO and Co-Founder of DoMore Diagnostics.
The study is expected to deliver evidence supporting the clinical utility of Histotype Px Colorectal as a prognostic biomarker in colorectal cancer and to inform future strategies for personalized adjuvant treatment.
DoMore Diagnostics has been awarded an Innovation Project for the Industrial Sector grant from the Research Council of Norway to fund this research.
About the FFCD
The Fédération Francophone de Cancérologie Digestive (FFCD) is a leading French academic non-profit organization dedicated to advancing the prevention, diagnosis, and treatment of digestive cancers. In addition to conducting high-quality, European multi-center clinical trials, the FFCD actively participates in translational research through partnerships with academic and industry stakeholders to drive innovation and improve care for patients with gastrointestinal malignancies.
About the CHU Dijon Bourgogne
The CHU Dijon Bourgogne is guided by a long-term strategic vision: becoming a national leader in care, research, and teaching, while playing a major role in prevention and ensuring equitable access to healthcare across the Bourgogne–Haute-Marne region thanks to its 1800 hospital beds and more than 9000 dedicated professionals. Ranked among the top 15 French hospitals for research, the CHU Dijon Bourgogne is ideally positioned at the heart of a major university campus and fosters a dynamic research and innovation ecosystem that works closely with expert teams focused on clinical care.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. While adjuvant chemotherapy (ACT) may be offered after primary surgery to prevent disease recurrence, overtreatment is prevalent. Up to 85% of patients treated for stage II and stage III disease do not actually benefit from ACT, but still suffer from its side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com